A coronariastenttel élo betegek perioperatív ellátása nem szívsebészeti beavatkozások esetén - I. Rész az antitrombotikus kezelés alapelvei a beültetett stentnek meefeleloen

Translated title of the contribution: Perioperative management of patients with coronary stent in case of interventions other than cardiac surgery - Part I. - Periopertive treatment of patients with coronary stent

E. Zima, Mezofi Miklós, Becker Dávid, Szabó György, B. Merkely, Pénzes István

Research output: Contribution to journalArticle

Abstract

Percutaneous coronary intervention (PCI) is meant to optimalise cardiac status, that is, short-term and long-term outcomes. It is known from large Western databases that stent implantation is performed in 77-85% of coronary interventions, which means hundreds of thousands of new patients with stent every year. The great majority of these patients has to take platelet aggregation inhibitors, namely acetylsalicylic acid and thienopyridin, most often clopidrogel. It presents a major therapeutic dilemma when these patients require noncardiac surgery. First, surgery should be performed with the least possible blood loss, which would be optimal if the platelet aggregation inhibitor therapy - that is indispensable for a certain period because of the stent - was suspended. Second, stent thrombosis has to be avoided, which can only be achieved if platelet aggregation inhibitor therapy is continued. The aim of our paper is to summarise the current guidelines and the risk estimation on the basis of our current knowledge in the perioperative management of patients with coronary stent. In the first part, we overview the platelet aggregation inhibitor agents, their mechanisms of effect, stent types and the minimal therapeutic period to be strictly observed, which depends on the type of stent.

Original languageHungarian
Pages (from-to)607-613
Number of pages7
JournalLege Artis Medicinae
Volume21
Issue number10
Publication statusPublished - Oct 2011

Fingerprint

Thoracic Surgery
Stents
Platelet Aggregation Inhibitors
Therapeutics
Percutaneous Coronary Intervention
Aspirin
Thrombosis
Databases
Guidelines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A coronariastenttel élo betegek perioperatív ellátása nem szívsebészeti beavatkozások esetén - I. Rész az antitrombotikus kezelés alapelvei a beültetett stentnek meefeleloen. / Zima, E.; Miklós, Mezofi; Dávid, Becker; György, Szabó; Merkely, B.; István, Pénzes.

In: Lege Artis Medicinae, Vol. 21, No. 10, 10.2011, p. 607-613.

Research output: Contribution to journalArticle

@article{3680d0b161ea434eb700a29d8f80135b,
title = "A coronariastenttel {\'e}lo betegek perioperat{\'i}v ell{\'a}t{\'a}sa nem sz{\'i}vseb{\'e}szeti beavatkoz{\'a}sok eset{\'e}n - I. R{\'e}sz az antitrombotikus kezel{\'e}s alapelvei a be{\"u}ltetett stentnek meefeleloen",
abstract = "Percutaneous coronary intervention (PCI) is meant to optimalise cardiac status, that is, short-term and long-term outcomes. It is known from large Western databases that stent implantation is performed in 77-85{\%} of coronary interventions, which means hundreds of thousands of new patients with stent every year. The great majority of these patients has to take platelet aggregation inhibitors, namely acetylsalicylic acid and thienopyridin, most often clopidrogel. It presents a major therapeutic dilemma when these patients require noncardiac surgery. First, surgery should be performed with the least possible blood loss, which would be optimal if the platelet aggregation inhibitor therapy - that is indispensable for a certain period because of the stent - was suspended. Second, stent thrombosis has to be avoided, which can only be achieved if platelet aggregation inhibitor therapy is continued. The aim of our paper is to summarise the current guidelines and the risk estimation on the basis of our current knowledge in the perioperative management of patients with coronary stent. In the first part, we overview the platelet aggregation inhibitor agents, their mechanisms of effect, stent types and the minimal therapeutic period to be strictly observed, which depends on the type of stent.",
keywords = "Non-cardiac surgery, Percutaneous coronary intervention, Platelet aggregation inhibition",
author = "E. Zima and Mezofi Mikl{\'o}s and Becker D{\'a}vid and Szab{\'o} Gy{\"o}rgy and B. Merkely and P{\'e}nzes Istv{\'a}n",
year = "2011",
month = "10",
language = "Hungarian",
volume = "21",
pages = "607--613",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "10",

}

TY - JOUR

T1 - A coronariastenttel élo betegek perioperatív ellátása nem szívsebészeti beavatkozások esetén - I. Rész az antitrombotikus kezelés alapelvei a beültetett stentnek meefeleloen

AU - Zima, E.

AU - Miklós, Mezofi

AU - Dávid, Becker

AU - György, Szabó

AU - Merkely, B.

AU - István, Pénzes

PY - 2011/10

Y1 - 2011/10

N2 - Percutaneous coronary intervention (PCI) is meant to optimalise cardiac status, that is, short-term and long-term outcomes. It is known from large Western databases that stent implantation is performed in 77-85% of coronary interventions, which means hundreds of thousands of new patients with stent every year. The great majority of these patients has to take platelet aggregation inhibitors, namely acetylsalicylic acid and thienopyridin, most often clopidrogel. It presents a major therapeutic dilemma when these patients require noncardiac surgery. First, surgery should be performed with the least possible blood loss, which would be optimal if the platelet aggregation inhibitor therapy - that is indispensable for a certain period because of the stent - was suspended. Second, stent thrombosis has to be avoided, which can only be achieved if platelet aggregation inhibitor therapy is continued. The aim of our paper is to summarise the current guidelines and the risk estimation on the basis of our current knowledge in the perioperative management of patients with coronary stent. In the first part, we overview the platelet aggregation inhibitor agents, their mechanisms of effect, stent types and the minimal therapeutic period to be strictly observed, which depends on the type of stent.

AB - Percutaneous coronary intervention (PCI) is meant to optimalise cardiac status, that is, short-term and long-term outcomes. It is known from large Western databases that stent implantation is performed in 77-85% of coronary interventions, which means hundreds of thousands of new patients with stent every year. The great majority of these patients has to take platelet aggregation inhibitors, namely acetylsalicylic acid and thienopyridin, most often clopidrogel. It presents a major therapeutic dilemma when these patients require noncardiac surgery. First, surgery should be performed with the least possible blood loss, which would be optimal if the platelet aggregation inhibitor therapy - that is indispensable for a certain period because of the stent - was suspended. Second, stent thrombosis has to be avoided, which can only be achieved if platelet aggregation inhibitor therapy is continued. The aim of our paper is to summarise the current guidelines and the risk estimation on the basis of our current knowledge in the perioperative management of patients with coronary stent. In the first part, we overview the platelet aggregation inhibitor agents, their mechanisms of effect, stent types and the minimal therapeutic period to be strictly observed, which depends on the type of stent.

KW - Non-cardiac surgery

KW - Percutaneous coronary intervention

KW - Platelet aggregation inhibition

UR - http://www.scopus.com/inward/record.url?scp=82055196747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82055196747&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 607

EP - 613

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 10

ER -